240 related articles for article (PubMed ID: 20347310)
1. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
Chia SY; Thike AA; Cheok PY; Tan PH
Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
[TBL] [Abstract][Full Text] [Related]
2. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
Bhargava R; Beriwal S; Dabbs DJ
Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens.
Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC
Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055
[TBL] [Abstract][Full Text] [Related]
4. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
[TBL] [Abstract][Full Text] [Related]
5. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.
Luo MH; Huang YH; Ni YB; Tsang JY; Chan SK; Shao MM; Tse GM
Hum Pathol; 2013 Jul; 44(7):1241-50. PubMed ID: 23332923
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
Kanner WA; Galgano MT; Stoler MH; Mills SE; Atkins KA
Int J Gynecol Pathol; 2008 Oct; 27(4):491-5. PubMed ID: 18753974
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
[TBL] [Abstract][Full Text] [Related]
8. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
Lopez-Bonet E; Pérez-Martínez MC; Martin-Castillo B; Alonso-Ruano M; Tuca F; Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Beltràn M; Bernadó L; Menendez JA
Breast Cancer Res Treat; 2011 Feb; 126(1):241-5. PubMed ID: 20978935
[No Abstract] [Full Text] [Related]
10. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study.
Raju U; Ma CK; Shaw A
Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106
[TBL] [Abstract][Full Text] [Related]
11. Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?
Richter-Ehrenstein C; Arndt J; Buckendahl AC; Eucker J; Weichert W; Kasajima A; Schneider A; Noske A
Breast Cancer Res Treat; 2010 Nov; 124(2):413-7. PubMed ID: 20872069
[TBL] [Abstract][Full Text] [Related]
12. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis.
Raica M; Cîmpean AM; Meche A; Alexa A; Suciu C; Mureşan A
Rom J Morphol Embryol; 2009; 50(3):341-7. PubMed ID: 19690758
[TBL] [Abstract][Full Text] [Related]
14. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
15. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
16. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
17. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
[TBL] [Abstract][Full Text] [Related]
18. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
19. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
20. Mammaglobin expression in primary, metastatic, and occult breast cancer.
Watson MA; Dintzis S; Darrow CM; Voss LE; DiPersio J; Jensen R; Fleming TP
Cancer Res; 1999 Jul; 59(13):3028-31. PubMed ID: 10397237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
